Ubs Group Ag Nuvalent, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Nuvalent, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 46,614 shares of NUVL stock, worth $3.93 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

46,614

Previous 53,395 12.7%

Holding current value

$3.93 Million

Previous $4.05 Million 17.73%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$67.44 - $112.17 $457,310 - $760,624	-6,781 Reduced 12.7%	46,614 $4.77 Million
Q2 2024 Aug 13, 2024	SELL	$62.76 - $81.61 $1.92 Million - $2.5 Million	-30,623 Reduced 36.45%	53,395 $4.05 Million
Q1 2024 May 13, 2024	BUY	$72.35 - $88.99 $245,049 - $301,409	3,387 Added 4.2%	84,018 $6.31 Million
Q4 2023 Feb 09, 2024	BUY	$42.42 - $80.28 $2.62 Million - $4.96 Million	61,763 Added 327.34%	80,631 $5.93 Million
Q3 2023 Nov 09, 2023	SELL	$39.12 - $49.85 $504,726 - $643,164	-12,902 Reduced 40.61%	18,868 $867,000
Q2 2023 Aug 11, 2023	BUY	$23.58 - $44.68 $31,337 - $59,379	1,329 Added 4.37%	31,770 $1.34 Million
Q1 2023 May 12, 2023	SELL	$25.42 - $33.52 $171,508 - $226,159	-6,747 Reduced 18.14%	30,441 $794,000
Q4 2022 Feb 08, 2023	BUY	$18.46 - $36.37 $686,490 - $1.35 Million	37,188 New	37,188 $1.11 Million
Q2 2022 Aug 10, 2022	SELL	$7.4 - $15.07 $10,574 - $21,535	-1,429 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$11.65 - $19.57 $1,526 - $2,563	131 Added 10.09%	1,429 $20,000
Q4 2021 Feb 14, 2022	BUY	$18.01 - $30.1 $8,752 - $14,628	486 Added 59.85%	1,298 $25,000
Q3 2021 Nov 15, 2021	BUY	$18.25 - $38.35 $14,819 - $31,140	812 New	812 $18,000

Others Institutions Holding NUVL

# of Institutions

209

Shares Held

59.5M

Call Options Held

450K

Put Options Held

619K

View Full List

About Nuvalent, Inc.

Ticker NUVL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,977,800
Market Cap $3.62B
Description
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...

More about NUVL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account